Baricitinib for the treatment of atopic dermatitis

Abstract

Atopic dermatitis is a common, chronic and recurrent inflammatory skin disease, which often appears in childhood but can last into adulthood. It negatively impacts patients, their families and society in general. There is a therapeutic unmet need, with patients requiring new drugs that are safe and effective. The increasing knowledge of the pathophysiology of AD and the role of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway in the development and maintenance of AD, has led to the development of agents blocking this intracellular signaling pathway, the JAK inhibitors. Baricitinib shows high selectivity for JAK1 and JAK2, making it appealing for the treatment of this condition. Phase II and phase III trials evaluated the efficacy and safety of baricitinib in the treatment of AD, and the results have been encouraging, showing a good efficacy and a favorable safety and tolerability profile. At the end of 2020, EMA approved baricitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, increasing the therapeutic option for this debilitating disease.

Keywords:

• Atopic dermatitis
• baricitinib
• JAK inhibitors
• JAK/STAT

Disclosure statement

Melo A has no conflicts of interest. Carrascosa JM has received honoraria for acting as a consultant and/or as a speaker from for Abbvie, Janssen, Novartis, Lilly, Leo-Pharma, Almirall, Amgen, Sandoz, Mylan, and Pfizer. Torres T has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Biogen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Fresenius Kabi, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, Sanofi, UCB.